Market Dynamics:The increasing product pipeline is estimated to significantly drive the growth of the lupus therapeutic market over the forecast period. Several pharmaceutical companies are investing extensively in R&D to develop novel biologics and small molecules for lupus treatment. For instance, GlaxoSmithKline is evaluating its BTK inhibitor otilimab in Phase II/III clinical trials as...
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Italiano
Russian
Romaian